STAT1 Signaling Is Not Regulated by a Phosphorylation-Acetylation Switch
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The treatment of cells with histone deacetylase inhibitors (HDACi) was reported to reveal the acetylation of STAT1 at lysine 410 and lysine 413 (O. H. Krämer et al., Genes Dev. 20:473-485, 2006). STAT1 acetylation was proposed to regulate apoptosis by facilitating binding to NF-κB and to control immune responses by suppressing STAT1 tyrosine phosphorylation, suggesting that STAT1 acetylation is a central mechanism by which histone deacetylase inhibitors ameliorate inflammatory diseases (O. H. Krämer et al., Genes Dev. 23:223-235, 2009). Here, we show that the inhibition of deacetylases had no bearing on STAT1 acetylation and did not diminish STAT1 tyrosine phosphorylation. The glutamine mutation of the alleged acetylation sites, claimed to mimic acetylated STAT1, similarly did not diminish the tyrosine phosphorylation of STAT1 but precluded its DNA binding and nuclear import. The defective transcription activity of this mutant therefore cannot be attributed to STAT1 acetylation but rather to the inactivation of the STAT1 DNA binding domain and its nuclear import signal. Experiments with respective cDNAs provided by the authors of the studies mentioned above confirmed the results reported here, further questioning the validity of the previous data. We conclude that the effects and potential clinical benefits associated with histone deacetylase inhibition cannot be explained by promoting the acetylation of STAT1 at lysines 410 and 413.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928 · cited 1×
“At present, the claims put forth in references 22 and 23 were found to be without experimental justification, as are attempts to link the protective effects of histone deacetylase inhibitors against cancer and inflammation to the Lys410/ Lys413 acetylation of STAT1 (4, 10, 17, 18, 34, 44).”
BackgroundIdentification of a Nuclear Stat1 Protein Tyrosine Phosphatase
ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., & Shuai, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5662-5668.2002 · Cited by 507
Acetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
GAS Elements: A Few Nucleotides with a Major Impact on Cytokine-Induced Gene Expression
DECKER, T., KOVARIK, P., & MEINKE, A. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.121 · Cited by 437 · cited 2×
“IFN- stimulation gives rise predominantly to STAT1/STAT2 heterodimers that bind together with another protein, IRF-9, to an unrelated DNA site (9, 15), such that relatively few STAT1 dimers capable of GAS binding remain.”
BackgroundMüller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., & Kerr, I. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06106.x · Cited by 411
Roger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A.-L., Reymond, M. K., Miconnet, I., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284711 · Cited by 341 · cited 1×
“This conclusion agrees with numerous previous studies, which reported the unchanged or even prolonged tyrosine phosphorylation of STAT1 at low HDACi concentrations similar to those used here (5, 33, 36).”
ResultRegulated nuclear import of the STAT1 transcription factor by direct binding of importin‐α
McBride, K. M., Banninger, G., McDonald, C., & Reich, N. C. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1754 · Cited by 289 · cited 1×
“In agreement with general NLS requirements, lysines in these positions facilitate the association of activated STAT1 with importin- , which is required for subsequent nuclear import (26, 29, 32).”
BackgroundDNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1
Meyer, T., Marg, A., Lemke, P., Wiesner, B., & Vinkemeier, U. (2003) · Genes & Development · doi:10.1101/gad.268003 · Cited by 161 · cited 3×
“used for immunoprecipitation (30) and Western blotting.”
BackgroundInfluentialSelf-citation
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
“While STAT1may be acetylated in some circumstances, others cannot reproduce the link between acetylation and dephosphorylation (Antunes et al. 2011).”
Regulation of STAT signaling by acetylation
Zhuang, S. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.007 · Cited by 195
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137
“However, the regulation of STAT1 activity by acetylation is currently under debate as Antunes and colleagues were unable to detect acetylation of STAT1 either in a resting state, or following HDACi or IFN treatment (50).”
BackgroundMethod
Metadata
- Authors
- Antunes, F., Marg, A., & Vinkemeier, U.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-07-01
- Volume
- 31
- Issue
- 14
- Pages
- 3029-3037
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2141570986
- Cited by
- 39
- References
- 8
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.